Discovery of new T cells and key genes in immunological diseases

Introduction

An international team of researchers led by Yasuhiro Murakawa from RIKEN Center for Integrative Medical Sciences (IMS) And Kyoto Universityidentified several rare types T cells employees and genes associated with immunological disorders. The results of the study were published in the journal The scienceoffer new insights into diseases such as multiple sclerosis, rheumatoid arthritis and asthma.

Innovative ReapTEC technology

The progress was made thanks to a new technology called ReapTEKwhich allowed the identification of genetic enhancers in rare T cell subtypes. These enhancers are regions of DNA that enhance the expression of other genes and can significantly affect the function of the T cells identified using nearly all of the ReapTEC technology. 63,000 active bidirectional amplifiers

in these rare cells, providing the basis for a better understanding of the mechanisms of immune-mediated diseases.

Public T-cell atlas

New T-cell atlas prepared by the researchers, is publicly available and should help in the development of new drugs for the treatment of immune-mediated diseases. T-helpers They play a decisive role in the regulation of the immune response and in the pathogenesis of autoimmune and allergic diseases.

Association with immune-mediated diseases

Using genome-wide association studies (GVAS), the researchers found that genetic variants of immune-mediated diseases were frequently found in bidirectional enhancer DNA of rare identified T cells. In contrast, genetic variants of neurological diseases did not show a similar pattern, highlighting the specificity of these enhancers for immune-mediated diseases.

Key findings and therapeutic applications

Between 63,000 bidirectional acceleratorsresearchers have determined 606 boosts which included genetic variants associated with 18 immune-mediated diseases. They also identified the specific genes that these enhancers target. For example, the gene Il7R was activated by an enhancer associated with inflammatory bowel disease.

Conclusion

This study not only provides a new methodology for studying T cell genetics, but also offers potential opportunities. therapeutic goals

to treat immune-mediated diseases. According to Murakawa, in the long term, these discoveries could lead to the development of new molecules to treat these diseases, which would greatly improve our understanding and treatment of immunological disorders. For more information, you can access the full article in the journal. The science.